Vor Biopharma Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Hi, good afternoon. And good morning for folks that are here on the West Coast.
So we'll get started with our next company, Vor Biopharma, where we have with us CFO, Nathan Jorgensen; CSO, Tirta Chakraborty. Great to have the Vor team with us here today. And for the audience, thank you for being part of this, and feel free to e-mail me directly questions at [email protected].
Obviously, the team -- Nathan, Tirta, you've had a very productive end of 2022. And on the back half of the syear, you had initiated manufacturing in house around your Cambridge headquarters. And in December, you obviously had the first clinical data with your trem-cel + Mylotarg combination. Throughout the course of the year, I believe you presented some updates from your multiplex projects. So we'll dig into all those different components one by one.
Questions & Answers
But at the highest level, Nathan, could you get us started about how we think
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
